MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 5, 2012, Pages 1017-1023

  Zhang, Hong Sheng ^a   Wu, Tong Chao ^a   Sang, Wei Wei ^a   Ruan, Zheng ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

AMPK; MiR 217; NF B; SIRT1

Indexed keywords

ADENYLATE KINASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 217; SIRTUIN 1; SYNAPTOTAGMIN I; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; DOWN REGULATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ADENYLATE KINASE; DOWN-REGULATION; ENZYME ACTIVATION; HELA CELLS; HIV LONG TERMINAL REPEAT; HUMANS; MICRORNAS; NF-KAPPA B; SIRTUIN 1; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84859172922     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.02.014     Document Type: Article

References (46)

1. Smith K., Powers K.A., Kashuba A.D., Cohen M.S. HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr. Opin. HIV AIDS 2011, 6:315-325.
2. Blas-Garcia A., Esplugues J.V., Apostolova N. Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr. Med. Chem. 2011, 18:2186-2195.
3. Pirrone V., Thakkar N., Jacobson J.M., Wigdahl B., Krebs F.C. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob. Agents Chemother. 2011, 55:1831-1842.
4. Al-Mawsawi L.Q., Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem 2011, 6:228-241.
5. Baba M. Recent status of HIV-1 gene expression inhibitors. Antiviral Res. 2006, 71:301-306.
6. Hakre S., Chavez L., Shirakawa K., Verdin E. Epigenetic regulation of HIV latency. Curr. Opin. HIV AIDS 2011, 6:19-24.
7. Choudhary S.K., Margolis D.M. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 2011, 51:397-418.
8. Lever A.M., Jeang K.T. Insights into cellular factors that regulate HIV-1 replication in human cells. Biochemistry 2011, 50:920-931.
9. Stevens M., De Clercq E., Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med. Res. Rev. 2006, 26:595-625.
10. Johri M.K., Mishra R., Chhatbar C., Unni S.K., Singh S.K. Tits and bits of HIV Tat protein. Expert Opin. Biol. Ther. 2011, 11:269-283.
11. Karn J. Tackling Tat. J. Mol. Biol. 1999, 293:235-254.
12. Col E., Gilquin B., Caron C., Khochbin S. Tat-controlled protein acetylation. J. Biol. Chem. 2002, 277:37955-37960.
13. Marzio G., Tyagi M., Gutierrez M.I., Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13519-13524.
14. Ott M., Dorr A., Hetzer-Egger C., Kaehlcke K., Schnolzer M., Henklein P., Cole P., Zhou M.M., Verdin E. Tat acetylation: a regulatory switch between early and late phases in HIV transcription elongation. Novartis Found. Symp. 2004, 259:182-193.
15. Pagans S., Pedal A., North B.J., Kaehlcke K., Marshall B.L., Dorr A., Hetzer-Egger C., Henklein P., Frye R., McBurney M.W., Hruby H., Jung M., Verdin E., Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 2005, 3:e41.
16. Neilson J.R., Sharp P.A. Small RNA regulators of gene expression. Cell 2008, 134:899-902.
17. Hobert O. Gene regulation by transcription factors and microRNAs. Science 2008, 319:1785-1786.
18. Grassmann R., Jeang K.T. The roles of microRNAs in mammalian virus infection. Biochim. Biophys. Acta 2008, 1779:706-711.
19. Klase Z., Winograd R., Davis J., Carpio L., Hildreth R., Heydarian M., Fu S., McCaffrey T., Meiri E., Ayash-Rashkovsky M., Gilad S., Bentwich Z., Kashanchi F. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 2009, 6:18.
20. Kaul D., Ahlawat A., Gupta S.D. HIV-1 genome-encoded hiv1-mir-H1 impairs cellular responses to infection. Mol. Cell. Biochem. 2009, 323:143-148.
21. Omoto S., Fujii Y.R. Regulation of human immunodeficiency virus 1 transcription by Nef microRNA. J. Gen. Virol. 2005, 86:751-755.
22. Omoto S., Ito M., Tsutsumi Y., Ichikawa Y., Okuyama H., Brisibe E.A., Saksena N.K., Fujii Y.R. HIV-1 Nef suppression by virally encoded microRNA. Retrovirology 2004, 1:44.
23. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5:253-295.
24. Kwon H.S., Ott M. The ups and downs of SIRT1. Trends Biochem. Sci. 2008, 33:517-525.
25. Kimpton J., Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 1992, 66:2232-2239.
26. Zhang H.S., Sang W.W., Wang Y.O., Liu W. Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation. J. Cell. Biochem. 2010, 110:1464-1470.
27. Zhang H.S., Sang W.W., Wang Y.O., Ruan Z. Akt/Nox2/NF-κB signaling pathway is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation. Arch. Biochem. Biophys. 2011, 505:266-272.
28. +-dependent SIRT1 activity. Life Sci. 2009, 85:484-489.
29. Zhang H.S., Ruan Z., Sang W.W. HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation. J. Cell. Physiol. 2011, 226:3385-3391.
30. Zhang H.S., Li H.Y., Zhou Y., Wu M.R., Zhou H.S. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation. Free Radic. Biol. Med. 2009, 47:261-268.
31. Zhang H.S., Wu M.R. SIRT1 regulates Tat induced HIV-1 transactivation through activating AMP-activated protein kinase. Virus Res. 2009, 146:51-57.
32. Yeung M.L., Bennasser Y., Myers T.G., Jiang G., Benkirane M., Jeang K.T. Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology 2005, 2:81.
33. Houzet L., Yeung M.L., de Lame V., Desai D., Smith S.M., Jeang K.T. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 2008, 5:118.
34. Nathans R., Chu C.Y., Serquina A.K., Lu C.C., Cao H., Rana T.M. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol. Cell 2009, 34:696-709.
35. Ahluwalia J.K., Khan S.Z., Soni K., Rawat P., Gupta A., Hariharan M., Scaria V., Lalwani M., Pillai B., Mitra D., Brahmachari S.K. Human cellular microRNA hsa-miR-29a interferes with viral Nef protein expression and HIV-1 replication. Retrovirology 2008, 5:117.
36. Huang J., Wang F., Argyris E., Chen K., Liang Z., Tian H., Huang W., Squires K., Verlinghieri G., Zhang H. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 2007, 13:1241-1247.
37. Triboulet R., Mari B., Lin Y.L., Chable-Bessia C., Bennasser Y., Lebrigand K., Cardinaud B., Maurin T., Barbry P., Baillat V., Reynes J., Corbeau P., Jeang K.T., Benkirane M. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007, 315:1579-1582.
38. Sung T.L., Rice A.P. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of Cyclin T1. PLoS Pathog. 2009, 5:e1000263.
39. Sun G., Li H., Wu X., Covarrubias M., Scherer L., Meinking K., Luk B., Chomchan P., Alluin J., Gombart A.F., Rossi J.J. Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res. Nov 10 2011, [Epub ahead of print].
40. Chiang K., Sung T.L., Rice A.P. Regulation of cyclin T1 and HIV-1 replication by miRNAs in resting CD4+ T lymphocytes. J. Virol. Dec 28 2011, [Epub ahead of print].
41. Chang J.R., Mukerjee R., Bagashev A., Del Valle L., Chabrashvili T., Hawkins B.J., He J.J., Sawaya B.E. HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs. J. Biol. Chem. 2011, 286:41125-41134.
42. Ott M., Schnolzer M., Garnica J., Fischle W., Emiliani S., Rackwitz H.R., Verdin E. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr. Biol. 1999, 9:1489-1492.
43. Mancebo H.S., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Peng J., Blau C., Hazuda D., Price D., Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 1997, 11:2633-2644.
44. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M.B., Price D.H. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 1997, 11:2622-2632.
45. Kwon H.S., Brent M.M., Getachew R., Jayakumar P., Chen L.F., McBurney M.W., Marmorstein R., Greene W.C., Ott M. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 2008, 3:158-167.
46. Fulco M., Sartorelli V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 2008, 7:3669-3679.